HYBRID EVENT: You can participate in person at Barcelona, Spain from your home or work.

9th Edition of World Congress on Infectious Diseases

June 25-27, 2026 | Barcelona, Spain

June 25 -27, 2026 | Barcelona, Spain
Infection 2025

Informatics approach to assess mumps vaccination

Speaker at Infection Conferences - Eriko Padron Regalado
Universidad Politecnica del Valle de Toluca, Mexico
Title : Informatics approach to assess mumps vaccination

Abstract:

Despite the high success of mumps vaccination as a public health measure, mumps outbreaks have been described in the United States. Differences in antibody cross-neutralization potential induced by the mumps vaccine (Jeryl-Lynn strain) has been pointed out as one of the reasons for these outbreaks. Immunoinformatic approaches have been shown to be valuable in the identification of B- and T-cell epitopes. In order to shed light on the cross-reactivity potential of the current mumps vaccine, we developed high-throughput computational workflows for B- and T-cell epitope identification and comparison using available informatic tools. The B-cell epitope prediction results agreed with empirical methods. Nevertheless, the T-cell epitope prediction results did not agree with the empirical data. The present workflow facilitated the analysis and comparison of circulating mumps virus sequences. In a yearly evaluation, the average number of mutations in the HN proteins did not increase since 2013. These results support the continuous evaluation of the mumps vaccine.

Biography:

Dr. Eriko Padron-Regalado has a Ph.D. in vaccine design from the University of Oxford and graduated in 2020. He then joined the Vaccine Immunology group of the Division of Viral Diseases of the U.S. Centers for Disease Control and Prevention (CDC) as a research fellow. He has a Master´s degree in molecular epidemiology from the King Abdullah University of Science and Technology (KAUST, Saudi Arabia). Among other accomplishments, he helped to characterize the vaccine platform called ChAdOx1, which was later exploited for the COVID-19 AstraZeneca-Oxford vaccine. Overall, he has worked in academia, government and industry, both national and international, strengthening vaccine development, evaluation and approval. Currently, his scientific publications have an average citation of 100 citations per paper.

Watsapp